BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
Retrieved on:
Wednesday, October 20, 2021
Boston Public Health Commission, COVID-19, Family, Clinical trial, CSE, Volunteering, Center, Risk, Bloomberg, Legislation, News, Immunotherapy, OTCQB, USPTO, Forward-looking statement, Severe acute respiratory syndrome coronavirus 2, Chinese Center for Disease Control and Prevention, Century, Centers for Disease Control and Prevention, World, World Health Organization, Vaccine, Immunity, Human, First pandemic, The New England Journal of Medicine, Private Securities Litigation Reform Act, SARS, Mortality, RNA transfection, Population, Patent, Marketing, ACE2, Company, FRA, Pharmaceutical industry
Sarbecoviruses, such as SARS-CoV-1 and SARS-CoV-2, all bind to the ACE2 receptor, which makes them highly transmissible.
Key Points:
- Sarbecoviruses, such as SARS-CoV-1 and SARS-CoV-2, all bind to the ACE2 receptor, which makes them highly transmissible.
- For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
- ( www.biovaxys.com ) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
- BioVaxys has multiple issued US patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.